Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
General23 hours agoMan charged with murder after alleged assault victim dies in Hervey Bay
-
General18 hours agoTaylor Swift breaks Adele’s record for most album sales in first week
-
Noosa News23 hours agoPublic health alert for nitazenes issued after person dies in Queensland
-
Noosa News21 hours agoNoosa Open Studios 2025 Art Trail kicks off today